SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

HUTCHMED’s Sovleplenib Gains FDA Orphan Drug Designation

The US FDA granted orphan drug designation to HUTCHMED’s sovleplenib for autoimmune hemolytic anemia.

Related stories